Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Ild

Study acronym: HIGHOXFILD
StatusUnknown
PhaseNot applicable
Started

Record status This record was last updated September 27, 2024 (before its estimated October 15, 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to evaluate the effects of high-flow nasal therapy (HFNT) oxygen compared to long-term oxygen therapy (LTOT) on dyspnea and quality of life in intersititial lung disease patients with chronic respiratory failure and persistent breathlessness in whom LTOT has already been initiated.
Trial Details
NCT Number NCT06617078
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions
(from sponsor)		 ILD
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov